Regulus Therapeutics
RGLS
#6967
Rank
$0.56 B
Marketcap
$8.16
Share price
0.00%
Change (1 day)
436.84%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -$47.43 Million USD

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -$46.2 Million USD a decrease over its 2023 earnings that were of -$29.44 Million USD. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -$47.43 Million2.66%
2024 -$46.2 Million56.97%
2023 -$29.44 Million6.51%
2022 -$27.64 Million2.53%
2021 -$26.96 Million93.59%
2020 -$13.93 Million-15.41%
2019 -$16.46 Million-64.46%
2018 -$46.31 Million-33.26%
2017 -$69.38 Million-13.98%
2016 -$80.66 Million44.77%
2015 -$55.72 Million-1.63%
2014 -$56.64 Million203.6%
2013 -$18.66 Million8.65%
2012 -$17.17 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
GlaxoSmithKline
GSK
$9.32 B-19,756.54%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
$9.10 B-19,287.12%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
$1.90 B-4,114.42%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
$13.09 B-27,699.15%๐Ÿ‡ฌ๐Ÿ‡ง UK
Alnylam Pharmaceuticals
ALNY
$0.13 B-374.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
-$0.11 Billion 129.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
$8.03 B-17,036.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-$0.12 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA